Cocrystal Pharma Inc COCP 深 滬
已收盤 02-06 16:00:00 美东时间
0.9699
+0.110
+12.75%
華盛通- 最 高0.988
- 今 開0.88
- 成交量 10.92万股
- 最 低 0.88
- 昨 收 0.8602
- 總市值 1336.92万
- 52周最高 2.67
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 0.8588
- 委 比 -33.33%
- 總股本 1378.41万
- 歷史最高 66.00
- 量 比 0.96
- 振 幅 12.56%
- 歷史最低 0.8588
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma, Inc. has received IRB approval to initiate a Phase 1b study for CDI-988, an oral antiviral candidate targeting norovirus infections. Enrollment begins Q1 2026, with the study evaluating CDI-988 for both prevention and treatment of norovirus, currently without approved therapies or vaccines. The double-blind, placebo-controlled study at Emory University will involve 40 healthy participants, assessing symptom reduction, viral shed...
2025-12-18 13:00
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its CFO and co-CEO, James Martin, will present updates on the company and its clinical progress at NobleCon 21 on December 3, 2025, at 10:00 am Eastern Time. The event will be held at Florida Atlantic University in Boca Raton, Florida. Investors and guests can attend with a discounted rate using the code COCPNOBLECON. A video webcast of the presentation will be available the following day on th...
2025-12-01 13:00
Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026Granted NIH SBIR award to advance influenza A/B
2025-11-14 21:29
Cocrystal Pharma Q3 EPS $(0.19) Beats $(0.21) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 61.22 percent increase over losses of $(0.49) per share from
2025-11-14 21:27
Cocrystal Pharma Awarded Roughly $500K Phase 1 Award From National Institutes of Health's National Institute of Allergy and Infectious Diseases To Support Development Of Antiviral Candidate To Treat Influenza A And B Infections
Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") announces it has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) National Institute of
2025-10-27 20:04
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Cocrystal Pharma, Inc. has received a $500,000 SBIR Phase I award from NIH's NIAID to develop a novel, oral, broad-spectrum antiviral for treating influenza A and B infections. The funds will support the characterization of lead molecules targeting the influenza polymerase complex. Sam Lee, PhD, President and co-CEO, emphasized the significance of non-dilutive funding for advancing the influenza program and validating the company's structure-base...
2025-10-27 12:00
Cocrystal Pharma Raises $4.75M in Direct Offering
Cocrystal Pharma ( ($COCP) ) has provided an update. On September 15, 2025, Coc...
2025-09-16 05:03
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock increased by 353.1% to $3.38 during Mond...
2025-09-15 20:10
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma raised $4.7 million via direct offering of 2.76 million shares at $1.70 each, with up to $8.3 million more from warrants exercisable at $1.50 per share. Proceeds will fund working capital and corporate purposes.
2025-09-12 13:43
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Cocrystal Pharma, Inc. announced that President Sam Lee highlighted CDI-988, a potential first oral antiviral for norovirus prevention and treatment, at the International Calicivirus Conference. CDI-988 showed favorable safety and tolerability in Phase 1 studies, with FDA clearance for a Phase 1b human challenge study. The drug targets a conserved region in viral proteases, leveraging Cocrystal's proprietary structure-based platform technology. N...
2025-09-12 12:00
